02.08.2011 • News • Alkermes • Biotechnology • Bilanz

Alkermes Q1 Loss Narrows Slightly

Integrated biotechnology company Alkermes, Monday reported net loss for the first quarter of $13.2 million, slightly narrower than the loss of $13.4 million in the year-ago quarter. Loss per share was unchanged at $0.14.

On average, 11 analysts polled by Thomson Reuters expected a loss of $0.12 per share for the quarter. Analysts' estimates typically exclude special items.

Results for the quarter included $5.7 million in share-based compensation expense and $9.5 million in costs related to the proposed merger with Elan Drug Technologies that is expected to close in September.

Excluding items, net income for the quarter was $1.9 million or $0.02 per share, compared to a net loss of $9.0 million or $0.09 per share last year.
Revenues for the quarter grew to $61.9 million from $42.3 million in the year-ago quarter. Ten Street analysts had a consensus revenue estimate of $52.7 million for the quarter.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.